Preimplantation Genetic Testing for Adult-Onset Neurodegenerative Disease: Considerations for Access, Utilization, and Counseling.


Journal

Neurology
ISSN: 1526-632X
Titre abrégé: Neurology
Pays: United States
ID NLM: 0401060

Informations de publication

Date de publication:
07 11 2023
Historique:
received: 10 01 2023
accepted: 20 06 2023
pmc-release: 07 11 2024
medline: 8 11 2023
pubmed: 19 8 2023
entrez: 18 8 2023
Statut: ppublish

Résumé

Preimplantation genetic testing for monogenic conditions (PGT-M), formerly called preimplantation genetic diagnosis, is a specialized assisted reproduction technique that aims to reduce the risk of a pregnancy inheriting a monogenic condition. Despite calls to increase awareness and prepare neurologists for discussing PGT-M with patients and their families, no guidelines currently exist. When introducing PGT-M to those who may be interested in using it, there are major factors for discussion, including (1) genetic considerations (e.g., requirement for a confirmed genetic diagnosis; timing of genetic test results); (2) practical considerations (e.g., access to PGT-M and genetic services); (3) technical considerations (e.g., factors that can affect the success rate of PGT-M); and (4) psychosocial and ethical considerations (e.g., predictive testing for asymptomatic family members; family dynamics and values). Here, our team of neurologists and specialized genetic counselors discusses the current state of genetic characterization in adult-onset neurodegenerative conditions and highlights the major factors that should be considered when discussing PGT-M with families.

Identifiants

pubmed: 37596038
pii: WNL.0000000000207736
doi: 10.1212/WNL.0000000000207736
pmc: PMC10663009
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

836-841

Informations de copyright

© 2023 American Academy of Neurology.

Références

Prog Mol Biol Transl Sci. 2021;177:91-107
pubmed: 33453944
Eur J Hum Genet. 2007 Apr;15(4):453-62
pubmed: 17245406
Nat Rev Neurol. 2014 Jul;10(7):417-24
pubmed: 24866878
J Genet Couns. 2022 Feb;31(1):176-187
pubmed: 34279057
J Genet Couns. 2022 Feb;31(1):261-268
pubmed: 34347921
J Genet Couns. 2014 Apr;23(2):202-11
pubmed: 23949612
Gene Ther. 2017 Sep;24(9):514-519
pubmed: 28561813
J Genet Couns. 2018 Aug;27(4):909-919
pubmed: 29248993
Health (London). 2010 Jan;14(1):41-56
pubmed: 20051429
J Reprod Med. 2014 Jul-Aug;59(7-8):385-92
pubmed: 25098029
Hum Reprod. 2011 Jul;26(7):1826-35
pubmed: 21558075
Reprod Biomed Online. 2022 May;44(5):839-852
pubmed: 35183447
Pract Neurol. 2017 Aug;17(4):275-281
pubmed: 28512206
J Med Ethics. 2020 Aug 19;:
pubmed: 32817410
Reprod Biol. 2021 Mar;21(1):100468
pubmed: 33321391
Fertil Steril. 2020 Oct;114(4):854-860
pubmed: 33040985
Fertil Steril. 2010 Sep;94(4):1239-1243
pubmed: 19815189
J Genet Couns. 2017 Oct;26(5):1070-1079
pubmed: 28265801
Neurol Genet. 2020 Dec 24;7(1):e538
pubmed: 33376800
Parkinsonism Relat Disord. 2020 Apr;73:72-84
pubmed: 32273229
Am J Med Genet A. 2021 Oct;185(10):2922-2928
pubmed: 34075706
Amyotroph Lateral Scler Frontotemporal Degener. 2015 Mar;16(1-2):114-9
pubmed: 25204983
Hum Reprod Update. 2013 May-Jun;19(3):304-15
pubmed: 23377865

Auteurs

Rachel A Paul (RA)

From the Department of Neurology (R.A.P., A.B., K.J., S.M.P., T.F.T., M.A., L.D.), University of Pennsylvania, Philadelphia; and Sarepta Therapeutics (T.B.), Cambridge, MA. rachel.paul3@pennmedicine.upenn.edu.

Aaron Baldwin (A)

From the Department of Neurology (R.A.P., A.B., K.J., S.M.P., T.F.T., M.A., L.D.), University of Pennsylvania, Philadelphia; and Sarepta Therapeutics (T.B.), Cambridge, MA.

Kelsey Johnson (K)

From the Department of Neurology (R.A.P., A.B., K.J., S.M.P., T.F.T., M.A., L.D.), University of Pennsylvania, Philadelphia; and Sarepta Therapeutics (T.B.), Cambridge, MA.

Sara Manning Peskin (S)

From the Department of Neurology (R.A.P., A.B., K.J., S.M.P., T.F.T., M.A., L.D.), University of Pennsylvania, Philadelphia; and Sarepta Therapeutics (T.B.), Cambridge, MA.

Thomas F Tropea (TF)

From the Department of Neurology (R.A.P., A.B., K.J., S.M.P., T.F.T., M.A., L.D.), University of Pennsylvania, Philadelphia; and Sarepta Therapeutics (T.B.), Cambridge, MA.

Meron Azage (M)

From the Department of Neurology (R.A.P., A.B., K.J., S.M.P., T.F.T., M.A., L.D.), University of Pennsylvania, Philadelphia; and Sarepta Therapeutics (T.B.), Cambridge, MA.

Tanya Bardakjian (T)

From the Department of Neurology (R.A.P., A.B., K.J., S.M.P., T.F.T., M.A., L.D.), University of Pennsylvania, Philadelphia; and Sarepta Therapeutics (T.B.), Cambridge, MA.

Laynie Dratch (L)

From the Department of Neurology (R.A.P., A.B., K.J., S.M.P., T.F.T., M.A., L.D.), University of Pennsylvania, Philadelphia; and Sarepta Therapeutics (T.B.), Cambridge, MA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH